Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 2/20 | 0.70 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.70 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.70 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.58 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.58 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.58 |
| ▸ | GBA1 | P04062 | 6/20 | 0.50 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 2/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.45 |
| ▸ | FUCA1 | P04066 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17718458 | 1.00 | GNAI3 (0.70) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL1044920 | 1.00 | GNAI3 (0.70) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL20746945 | 1.00 | GNAI3 (0.70) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL31020849 | 1.00 | GNAI3 (0.70) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL9155873 | 1.00 | GNAI3 (0.70) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL24210534 | 1.00 | GNAI3 (0.70) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL530708 | 0.97 | — | — | |
| SCHEMBL8880833 | 0.91 | GNAI3 (0.61) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL21696335 | 0.91 | GNAI3 (0.61) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL21367529 | 0.91 | GNAI3 (0.66) | GNAI3GNAO1GNAI1S1PR4S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10364267-B2 | Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-07-30 | — | — | US | disclosed |
| CN-108602955-A | The compound and composition used in process for photocuring, the process for photocuring | 富士胶片和光纯药株式会社 | 2018-09-28 | — | — | CN | disclosed |
| US-20170240585-A1 | DEUTERATED BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2017-08-24 | — | — | US | disclosed |
| US-9707000-B2 | Biodegradable nerve guides | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160122386-A1 | V1A RECEPTOR AGONISTS | OCELOT BIO, INC. | 2016-05-05 | — | — | US | disclosed |
| US-20080167500-A1 | Process for the Preparation of a Diastereomerically Enriched Compound | DSM IP ASSETS B.V. (NL) | 2008-07-10 | — | — | US | disclosed |
| CN-1989097-A | Process for the preparation of a diastereomerically enriched compound | DSM IP ASSETS BV (NL) | 2007-06-27 | — | — | CN | disclosed |
| EP-1778620-A1 | PROCESS FOR THE PREPARATION OF A DIASTEREOMERICALLY ENRICHED COMPOUND | DSMIP Assets B.V. (NL) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006008171-A1 | PROCESS FOR THE PREPARATION OF A DIASTEREOMERICALLY ENRICHED COMPOUND | DSM IP ASSETS B.V. (NL) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10364267-B2 | Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | NR1H4, GPBAR1, SLC10A1 | GNAI3 326/4885GNAO1 279/4885GNAI1 372/4885 |
| US-20170240585-A1 | DEUTERATED BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | NR1H4, GPBAR1, SLC10A1 | GNAI3 326/4885GNAO1 279/4885GNAI1 372/4885 |
| US-20080167500-A1 | Process for the Preparation of a Diastereomerically Enriched Compound | C1S, C1R, C9 | GNAI3 2349/4885GNAO1 2008/4885GNAI1 3100/4885 |
| US-20160122386-A1 | V1A RECEPTOR AGONISTS | AVPR2, AVPR1A, AVPR1B | GNAI3 882/4885GNAO1 564/4885GNAI1 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.